Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
2.470
-0.120 (-4.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Top 4 Health Care Stocks That May Crash This Month
↗
December 20, 2023
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
↗
December 14, 2023
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 14, 2023
Via
Benzinga
Analyst Expectations for Esperion Therapeutics's Future
↗
November 13, 2023
Via
Benzinga
5 Analysts Have This to Say About Esperion Therapeutics
↗
August 02, 2023
Via
Benzinga
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
December 14, 2023
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
December 14, 2023
It's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning!
Via
InvestorPlace
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
December 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
November 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
November 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 04, 2023
Via
Benzinga
"CLEAR" Progress At Esperion
↗
September 16, 2023
Esperion Therapeutics, Inc. continues to showcase their positive CLEAR data, with two oral presentations at the European Society of Cardiology 2023 Congress. Here is a closer look at some highlights.
Via
Talk Markets
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023
From
Esperion Therapeutics, Inc.; The American College of Cardiology
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 30, 2023
Via
Benzinga
Why Is Esperion Therapeutics Stock Trading Higher Today?
↗
August 28, 2023
Esperion Therapeutics Inc (NASDAQ: ESPR) announced the presentation of results from two CLEAR Outcomes Study Late-Breakers at the European
Via
Benzinga
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
June 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
